With the only approved complement therapeutic, Soliris, on the market for over a decade, the industry is overflowing with companies in clinical translation in a race for the next approval. The 2nd Complement-based Drug Development Summit encapsulates this excitement and provides one platform for every leading complement company to network and learn in an effort to overcome common challenges including:

Identify which Common Indication will Benefit Most: As the industry delves into targeting common disease indications, this meeting will explore which indication has the most potential for clinical success.

The Role of Complement in the CNS: Understand the biology of complement in the CNS and explore which complexes can be targeted to treat neurological disorders.

Last year we brought together the complement community to explore the potential of complement inhibition in rare diseases. This year we are getting bigger and better by exploring the wider potential of complement therapy in rare and common disease indications.

Attend this meeting to gain clear clinical understanding of the potential role of complement in common indications and identify which indication will be the next big opportunity for complement-based therapeutics. Register today!

Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

Scoop Line(Instant Information Request)The easiest way to ask questions and request information from the PR community.

Advanced SearchDrill down, dig deep, for media information the way you want it.